Is It Worthwhile to Add Dipivefrin HCl 0.1 % to Topical β1-, β2-blocker Theraphy?

Autor:	Kyle A. Parrow, Young J. Hong, Dian-Xiong Shi, Dong H. Shin, Beverly McCarty
Rok vydání:	1989
Předmět:	Dipivefrin Hydrochloride Intraocular pressure Dipivefrine genetic structures Dipivefrin business.industry medicine.medical_treatment Glaucoma Ocular hypertension Eye drop medicine.disease eye diseases Ophthalmology Regimen Anesthesia medicine sense organs business medicine.drug
Zdroj:	Ophthalmology. 96:1338-1342
ISSN:	0161-6420
DOI:	10.1016/s0161-6420(89)32737-0
Popis:	In a prospective study, the addition of dipivefrin hydrochloride 0.1 twice daily to one eye of 32 patients with early primary open-angle glaucoma or ocular hypertension, maintained on a bilateral β 1 -, β 2 -blocker twice daily, resulted in a significant decrease of mean intraocular pressure (IOP) from 22.7 ± 3.9 to 20.2 ± 3.4 mmHg at 1 week ( P = 0.0001) and to 21.0 ± 3.8 mmHg at 12 weeks ( P 1 -, β 2 -blocker regimen.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3960064a7e13386bf48e0a2f94e2325d https://doi.org/10.1016/s0161-6420(89)32737-0 Zobrazit plný text záznamu